Wednesday, 08 Apr 2020

You are here

DMARD Inertia by Registry Rheumatologists

A registry study of metric use (primarily RAPID3 and CDAI) in the treatment of rheumatoid arthritis (RA) patients shows that, even in the face of moderate or high disease activity, treatment changes by rheumatologists were relatively low (35.6–54.6%).

Researchers used data from the ACR supported Rheumatology Informatics System for Effectiveness (RISE) registry to assess the influence of disease activity measuress on treatment use over 12 months.

RAPID3 (78.9%) and the Clinical Disease Activity Index (CDAI) (34.2%) were most commonly used by rheumatologists in this registry.  Despite the use of measurements (required for inclusion), evidence of treat-to-target practices were lacking in many patients.

During the one year follow-up, patients with moderate or high disease activity (by both RAPID3 and CDAI) DMARD changes (additions/switches) were seen in these subgroups:

  • DMARD monotherapy = 62%
  • Biologic monotherapy = 57%
  • Combination csDMARDs = 34%
  • Combination DMARD + Biologic = 45%

Treament changes were less frequent when there was disagreement between RAPID3 and CDAI; specifically when RAPID3 showed moderate/high disease activity, but the CDAI showed low activity:

  • DMARD monotherapy = 35%
  • Biologic monotherapy = 52%
  • Combination csDMARDs = 12%
  • Combination DMARD + Biologic = 18%

Treatment changes were less likely in the elderly (age ≥75 years; adjusted odds ratio [OR 0.63), those treated with combination csDMARDs (OR 0.45) or combination therapy with bDMARDs (OR 0.30).

Only 1/3 to 2/3 of RA patients with moderate/high disease activity had a significant treatment change, suggesting that measurement alone is not enough to overcome the inertia of treatment escalation in RA.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Need for Disruptive Innovation in Rheumatology

A full-read, novel Viewpoint article published in the Annals of Rheumatic Disease (Huizinga TWJ, et al) spotlights a recent international meeting of big thinkers, scientific collaborators and industry dedicated to innovation in rheumatology.

Airway Inflammation Drives Rheumatoid Risk

A cohort analysis of the Nurses' Health Study suggests that asthma and COPD are associated with increased risk for incident rheumatoid arthritis (RA), independent of smoking- thus airway inflammation may be an important factor in the evolution of pre-cllnical RA.

Folate Levels Protect from CV Mortality in RA

In a study of rheumatoid arthritis (RA) patients, JAMA reports that serum folate level of greater than 4.3 ng/mL was associated with lower CV mortality risk.

A cohort study from the third National Health and Nutrition Examination Survey (1988-1994) and 2011 compared assess the risk of CV mortality in 683 RA patients based on their serum folate levels.

Bariatric Surgery Improves Rheumatoid Activity

Obesity is a risk factor for the onset of rheumatoid arthritis (RA) and may also an impediment to optimal DMARD and biologic responses.  A new study has shown that after 1 year, obese RA patients undergoing bariatric surgery with weight loss had significantly lower disease activity.

Seronegativity on the Rise in RA

Although the overall incidence rates of rheumatoid arthritis (RA) have remained stable over recent decades, there has been a significant increase in seronegative cases, a retrospective study showed.